-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Global Medical Marijuana Market Forecast to 2028 - Featuring Aphria, Canopy Growth, CanaQuest Medical and GW Pharmaceuticals Among Others - ResearchAndMarkets.com
Global Medical Marijuana Market Forecast to 2028 - Featuring Aphria, Canopy Growth, CanaQuest Medical and GW Pharmaceuticals Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Medical Marijuana Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Application, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.
The medical marijuana market was valued at US$ 11,706.50 million in 2021 and is likely to reach value of US$ 40,027.59 million by 2028; it is estimated to grow at a CAGR of 19.2% from 2022 to 2028.
The report highlights trends prevailing in the market and factors driving the medical marijuana market. The market growth is attributed to increasing approvals of medical marijuana products and rising acceptance of the medicinal use of marijuana. However, the illegal use of cannabis as a street drug and misconceptions regarding marijuana limit the market growth.
Medical marijuana is in its introduction stage in the medical health industry. It is a potent product accepted globally, where Chinese medicines are already being manufactured using these plants, and that too with a long history associated. Medical marijuana remains a significant influence in the healthcare industry to treat cases that are not entirely advisable with traditional medicines. Medical marijuana is just a typical marijuana plant that is processed to get the fundamental composition of cannabinoids, which is necessary to synthesize the product to be in use.
Countries in North America have legalized the use and cultivation of medical cannabis. For instance, in 2012, Uruguay became the first country in the world to legalize the recreational use of cannabis. Similarly, in 2014, Brazil authorized the use of medical cannabis, and in 2016, it approved the import of medications based on CBD oil and products made from THC and marijuana flowers.
In 2017, Peru approved a law regulating the medicinal and therapeutic use of cannabis and its derivatives. In 2018, the Government of Canada passed the Cannabis Act, which created a strict legal framework for controlling the production, distribution, sale, and possession of cannabis across Canada. In the US, as of February 2022, marijuana was legalized in 37 states and the District of Columbia. In the past few years, Mexico, Luxembourg, and Lesotho, among others, have joined the list of countries to legalize the use of marijuana for medical applications.
However, despite widespread legalization of the use of cannabis, its legal cultivation and production have earlier been mostly limited to developing countries. In September 2019, the Ministry of Commerce, Agriculture, and Fisheries of Jamaica announced a partnership with Harvard International Phytomedicines and Medical Cannabis Institute (HIPI) to conduct research on the pharmacological benefits of marijuana. At the same time, Jamaica aims to capitalize on this partnership and utilize this opportunity to grow and develop its national marijuana industry.
Market Dynamics
Drivers
- Increasing Approvals of Medical Marijuana Products
- Rising Acceptance of Medicinal Use of Marijuana in America
Restraints
- Illegal Use of Cannabis as Street Drug and Misconceptions Regarding Marijuana
Opportunities
- Increase in Job Opportunities in Marijuana Industry
Future Trends
- Widespread Distribution of Medical Marijuana
Companies Mentioned
- Aphria, Inc.
- Canopy Growth Corporation
- CanaQuest Medical Corporation
- GW Pharmaceuticals
- Organigram Holdings Inc.
- VIVO Cannabis Inc
- Panaxia Pharmaceutical Industries Ltd
- Phoena Holdings Inc.
- Emerald Health Therapeutics Inc.
- MARICANN INC
For more information about this report visit
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
DUBLIN--(BUSINESS WIRE)--The "Medical Marijuana Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Application, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.
都柏林--(美国商业资讯)--“到2028年医用大麻市场预测——按产品、应用、分销渠道和地理位置划分的 COVID-19 影响和全球分析” 报告已添加至 ResearchandMarkets.co 提供。
The medical marijuana market was valued at US$ 11,706.50 million in 2021 and is likely to reach value of US$ 40,027.59 million by 2028; it is estimated to grow at a CAGR of 19.2% from 2022 to 2028.
2021年,医用大麻市场的价值为117.065亿美元,到2028年可能达到40.2759亿美元;据估计,从2022年到2028年,医用大麻市场将以19.2%的复合年增长率增长。
The report highlights trends prevailing in the market and factors driving the medical marijuana market. The market growth is attributed to increasing approvals of medical marijuana products and rising acceptance of the medicinal use of marijuana. However, the illegal use of cannabis as a street drug and misconceptions regarding marijuana limit the market growth.
该报告重点介绍了市场的当前趋势和推动医用大麻市场的因素。市场的增长归因于医用大麻产品批准的增加以及对大麻药用用途的接受程度的提高。但是,非法使用大麻作为街头毒品以及对大麻的误解限制了市场的增长。
Medical marijuana is in its introduction stage in the medical health industry. It is a potent product accepted globally, where Chinese medicines are already being manufactured using these plants, and that too with a long history associated. Medical marijuana remains a significant influence in the healthcare industry to treat cases that are not entirely advisable with traditional medicines. Medical marijuana is just a typical marijuana plant that is processed to get the fundamental composition of cannabinoids, which is necessary to synthesize the product to be in use.
医用大麻正处于医疗健康行业的引入阶段。它是一种全球公认的强效产品,中国已经在使用这些植物生产中药,而且历史悠久。医用大麻仍然对医疗保健行业产生重大影响,可以治疗不完全建议使用传统药物的病例。医用大麻只是一种典型的大麻植物,经过加工获得大麻素的基本成分,而大麻素是合成要使用的产品所必需的。
Countries in North America have legalized the use and cultivation of medical cannabis. For instance, in 2012, Uruguay became the first country in the world to legalize the recreational use of cannabis. Similarly, in 2014, Brazil authorized the use of medical cannabis, and in 2016, it approved the import of medications based on CBD oil and products made from THC and marijuana flowers.
北美国家已将医用大麻的使用和种植合法化。例如,2012年,乌拉圭成为世界上第一个将娱乐性使用大麻合法化的国家。同样,2014年,巴西批准使用医用大麻,2016年,它批准进口基于CBD油的药物以及由四氢大麻酚和大麻花制成的产品。
In 2017, Peru approved a law regulating the medicinal and therapeutic use of cannabis and its derivatives. In 2018, the Government of Canada passed the Cannabis Act, which created a strict legal framework for controlling the production, distribution, sale, and possession of cannabis across Canada. In the US, as of February 2022, marijuana was legalized in 37 states and the District of Columbia. In the past few years, Mexico, Luxembourg, and Lesotho, among others, have joined the list of countries to legalize the use of marijuana for medical applications.
2017年,秘鲁批准了一项规范大麻及其衍生物的药用和治疗用途的法律。2018年,加拿大政府通过了《大麻法》,该法为控制加拿大各地的大麻生产、分销、销售和持有建立了严格的法律框架。在美国,截至2022年2月,大麻在37个州和哥伦比亚特区合法化。在过去的几年中,墨西哥、卢森堡和莱索托等国已加入将大麻用于医疗用途合法化的国家名单。
However, despite widespread legalization of the use of cannabis, its legal cultivation and production have earlier been mostly limited to developing countries. In September 2019, the Ministry of Commerce, Agriculture, and Fisheries of Jamaica announced a partnership with Harvard International Phytomedicines and Medical Cannabis Institute (HIPI) to conduct research on the pharmacological benefits of marijuana. At the same time, Jamaica aims to capitalize on this partnership and utilize this opportunity to grow and develop its national marijuana industry.
但是,尽管大麻的使用普遍合法化,但大麻的合法种植和生产以前主要限于发展中国家。2019年9月,牙买加商业、农业和渔业部宣布与哈佛国际植物医学和医用大麻研究所(HIPI)合作,对大麻的药理益处进行研究。同时,牙买加旨在利用这种伙伴关系,利用这个机会发展和发展其国家大麻产业。
Market Dynamics
市场动态
Drivers
司机
- Increasing Approvals of Medical Marijuana Products
- Rising Acceptance of Medicinal Use of Marijuana in America
- 增加对医用大麻产品的批准
- 美国对大麻药用的接受度越来越高
Restraints
约束
- Illegal Use of Cannabis as Street Drug and Misconceptions Regarding Marijuana
- 非法使用大麻作为街头毒品以及对大麻的误解
Opportunities
机会
- Increase in Job Opportunities in Marijuana Industry
- 大麻行业的就业机会增加
Future Trends
未来趋势
- Widespread Distribution of Medical Marijuana
- 医用大麻的广泛分布
Companies Mentioned
提及的公司
- Aphria, Inc.
- Canopy Growth Corporation
- CanaQuest Medical Corporation
- GW Pharmaceuticals
- Organigram Holdings Inc.
- VIVO Cannabis Inc
- Panaxia Pharmaceutical Industries Ltd
- Phoena Holdings Inc.
- Emerald Health Therapeutics Inc.
- MARICANN INC
- Aphria, Inc.
- Canopy GROWT
- CanaQuest 医疗公司
- GW 制药
- Organigram Holdings
- VIVO 大麻公司
- 泛夏制药工业有限公司
- 菲娜控股公司
- 埃默拉尔健康疗法公司
- MARICANN INC
For more information about this report visit
有关此报告的更多信息,请访问
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
ResearchandMarket
劳拉·伍德,高级新闻经理
press@researchandmarkets.com
如需了解欧洲安全局的办公时间,请致电 1-917-300-0470
如需美国/加拿大免费电话,请致电 1-800-526-8630
如需了解格林尼治标准时间办公时间,请致电 +353-1-416-8900
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧